加载中
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
前收盘价
US$4.24
−US$0.02 · -0.47%
盘中时间采用ET。市场数据可能有所延迟。
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
日内区间
当前US$4.24
52周区间
当前US$4.24
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
31
偏贵
情绪
46
多空交织
风险
56
风险偏高
动量
38
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
日内区间
当前US$4.24
52周区间
当前US$4.24
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 80万 USD | 350万 USD | 916万 USD | 1561.8万 USD | 3098.5万 USD |
| 销货成本 | 103.3万 USD | 152.6万 USD | 102万 USD | 6432.1万 USD | 4710.8万 USD |
| 毛利 | −23.3万 USD | 197.4万 USD | 814万 USD | −4870.3万 USD | −1612.3万 USD |
| 研究与开发 | 2852.5万 USD | 3210.9万 USD | 5965.2万 USD | 6432.1万 USD | 4710.8万 USD |
| 销售、一般及管理费用 | 2072.6万 USD | 839.1万 USD | 2492.5万 USD | 2220.1万 USD | 1801.5万 USD |
| 营业费用 | 4821.8万 USD | 3897.4万 USD | 8355.7万 USD | 2220.1万 USD | 1801.5万 USD |
| 利息收入 | 203.5万 USD | 737.3万 USD | 711.1万 USD | 214.9万 USD | 2.3万 USD |
| 折旧和摊销 | 103.3万 USD | 152.6万 USD | 102万 USD | 75.1万 USD | 54.4万 USD |
| 营业利润 | −4845.1万 USD | −3700万 USD | −7541.7万 USD | −7090.4万 USD | −3413.8万 USD |
| 净利润 | −4534.9万 USD | −3656.8万 USD | −6816.6万 USD | −6876.5万 USD | −3411.5万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$1.33
下跌空间 68.63%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
